Tag: Albireo Pharma

April 11, 2019

Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat

Albireo Pharma (NASDAQ:ALBO) has announced that its investigational new drug application (IND) cleared the 30-day review from the US Food...
October 17, 2018

Albireo Receives FDA Fast Track Designation for A4250

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food...
June 12, 2018

FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher

Albireo Pharma (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food...